AAX Biotech AB is thrilled to announce that we have successfully raised €7 million in a recent funding round, enabling us to further our mission of revolutionizing antibody-based medicine. Founded by esteemed scientists Mats AA Persson and Daniel X Johansson, we emerged from the prestigious Karolinska Institutet with a vision to reshape the biopharmaceutical landscape. With our cutting-edge technologies, Seqitope™ and Opti-mAb™, we specialize in next-generation antibody therapeutics that address some of the most significant unmet medical needs. Seqitope™ empowers us to conduct high-resolution and high-throughput epitope mapping, which is crucial for the rapid development of effective therapeutics against a variety of conditions, including cancer, autoimmune disorders, and neurological diseases. On the other hand, our Opti-mAb™ technology enhances the stability and expression levels of single-chain variable fragments, paving the way for innovative immunotherapeutics such as bispecific antibodies and CAR-T cell therapies. With our newly acquired funding, we plan to expand our R&D efforts, accelerate our product development pipeline, and solidify our position as a leading partner in the global biopharmaceutical industry. We are excited about the future and remain committed to not only advancing our proprietary technologies but also to fostering collaborations that will yield groundbreaking therapies for patients worldwide. This investment marks a crucial step forward in our quest to bring transformative medical solutions to those who need them most.





